NEWS IN BRIEF

Trial duration reduced by Site Contracts App, says KMR

By Flora Southey contact

- Last updated on GMT

(Image: iStock/Poike)
(Image: iStock/Poike)

Related tags: Clinical trial

KMR Group has launched a clinical application using CRO data to help improve contract cycle times.

The R&D analysis firm said the online platform, the Site Contracts Application, holds information regarding more than 100,000 Phase II and III clinical contracts from approximately 100 countries.

The firm said the application will help firms reduce contract cycle times - the duration between protocol approval and clinical trial report - and inform plans based on study phase, whether the site is independent or public, budget cycle time, therapy area, and location.

“With increasingly complex and long cycle times for investigative site clinical trial contracts, the Site Contracts Application provides previously unavailable industry contract benchmarks,” ​said KMR.

Anyone involved with incorporating site contract cycle times into overall trial plans will benefit from this application, added president Linda Martin.

According to the firm, more than 20 firms are represented in the application, with data dating back to 2010.

In 2016, KMR Group launched​ an online clinical trial performance application to help inform firms on trial performance, recruitment, and site metrics data.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us

Products

View more

Webinars